The National Institute on Neurological Disorders and Stroke (NINDS) intends to modify an existing sole-source contract with Curia Global, Inc. to increase the maximum value by $30,145,159, raising the total to $69,645,159. This modification supports the continuation of medicinal chemistry services for therapeutic development, including compound synthesis, ADMET studies, and computational chemistry, essential for advancing preclinical candidates toward IND filings. The contract’s ordering period runs from March 16, 2018, to March 15, 2028, with no changes to this timeline. Services are performed to support NIH programs, primarily focused on neurotherapeutics, with potential use by other NIH Institutes. The location for performance is not specified in the description.